THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO C.
SCORE: A STRAIGHTFORWARD AND RELIABLE PREOF
RECURRENCE AFTER RADICAL PROSTATECTOMY

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Changing Face of Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 8146-8151.	1.6	293
2	Management of High Risk Metastatic Prostate Cancer: Defining Risk at the Time of Initial Treatment Failure. Journal of Urology, 2006, 176, S57-60; discussion S55-6.	0.4	2
3	Impact of Increased Number of Biopsies on the Nature of Prostate Cancer Identified. Journal of Urology, 2006, 176, 63-69.	0.4	45
4	Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE. Urology, 2006, 68, 1242-1247.	1.0	19
5	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006, 107, 2384-2391.	4.1	129
7	The Relationship Between Anxiety and Time to Treatment for Patients With Prostate Cancer on Surveillance. Journal of Urology, 2007, 178, 826-832.	0.4	195
8	Validity of the CAPRA Score to Predict Biochemical Recurrence-Free Survival After Radical Prostatectomy. Results From a European Multicenter Survey of 1,296 Patients. Journal of Urology, 2007, 178, 1957-1962.	0.4	66
9	Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. Journal of Urology, 2007, 178, S14-9.	0.4	368
10	Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years. BJU International, 2007, 99, 1409-1414.	2.5	10
11	Diet and Lifestyle Interventions in Active Surveillance Patients with Favorable-Risk Prostate Cancer. Current Treatment Options in Oncology, 2007, 8, 173-196.	3.0	16
12	High-risk prostate cancer in the United States, 1990–2007. World Journal of Urology, 2008, 26, 211-218.	2.2	173
13	Watchful waiting versus active surveillance: Appropriate patient selection. Current Urology Reports, 2008, 9, 211-216.	2.2	10
14	Active surveillance for early-stage prostate cancer. Cancer, 2008, 112, 1650-1659.	4.1	252
15	An updated catalog of prostate cancer predictive tools. Cancer, 2008, 113, 3075-3099.	4.1	238
16	Prostate cancer risk assessment. Cancer, 2008, 113, 3062-3066.	4.1	16
17	Does the Extent of Carcinoma in Prostatic Biopsies Predict Prostate-Specific Antigen Recurrence? A Systematic Review. European Urology, 2008, 54, 728-739.	1.9	34
18	External Validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score. Urology, 2008, 72, 396-400.	1.0	50
19	Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy. Urology, 2008, 72, S12-S24.	1.0	114

#	ARTICLE	IF	CITATIONS
20	Prostate Biopsy Patterns in the CaPSURE Database: Evolution With Time and Impact on Outcome After Prostatectomy. Journal of Urology, 2008, 179, 136-140.	0.4	18
21	Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature. Clinical Cancer Research, 2008, 14, 4400-4407.	7.0	252
22	Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 102-110.	2.5	18
23	Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nature Reviews Urology, 2008, 5, 277-283.	1.4	17
24	Inventory of prostate cancer predictive tools. Current Opinion in Urology, 2008, 18, 279-296.	1.8	73
25	Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. Expert Review of Anticancer Therapy, 2009, 9, 939-951.	2.4	8
26	Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy. Journal of Clinical Oncology, 2009, 27, 4306-4313.	1.6	115
28	Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. Journal of the National Cancer Institute, 2009, 101, 878-887.	6.3	287
29	Development of a prostate cancer metagram. Cancer, 2009, 115, 3039-3045.	4.1	20
30	Watchful waiting versus active surveillance: Appropriate patient selection. Current Prostate Reports, 2009, 7, 5-10.	0.1	0
31	Advances and future directions in management of prostate cancer. Indian Journal of Surgery, 2009, 71, 337-341.	0.3	0
32	Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?. BJU International, 2009, 103, 603-608.	2.5	21
33	Comparative Analysis of Surgical Margins Between Radical Retropubic Prostatectomy and RALP: Are Patients Sacrificed During Initiation of Robotics Program?. Urology, 2009, 73, 567-571.	1.0	60
34	Critical review of prostate cancer predictive tools. Future Oncology, 2009, 5, 1555-1584.	2.4	162
35	Predicting Prostate Cancer Biochemical Recurrence Using a Panel of Serum Proteomic Biomarkers. Journal of Urology, 2009, 181, 1407-1414.	0.4	36
36	Mack Roach III, MD, Expert Radiation Oncologist and Prostate Cancer Specialist, Par Excellence!. Journal of the National Medical Association, 2009, 101, 1180-1182.	0.8	0
37	Prostate-specific antigen screening: pro. Current Opinion in Urology, 2010, 20, 185-188.	1.8	19
38	A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 148-154.	4.9	12

#	ARTICLE	IF	CITATIONS
39	Chemotherapy Foundation Symposium XXVIII Innovative Cancer Therapy For Tomorrow Abstracts 2010. Current Treatment Options in Oncology, 2010, 11, 1-104.	3.0	9
40	Reporting methods in studies developing prognostic models in cancer: a review. BMC Medicine, 2010, 8, 20.	5.5	160
41	Reporting performance of prognostic models in cancer: a review. BMC Medicine, 2010, 8, 21.	5.5	156
42	Head-to-Head Comparison of the Three Most Commonly Used Preoperative Models for Prediction of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2010, 57, 562-568.	1.9	69
44	Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. European Urology, 2010, 58, 687-700.	1.9	132
45	Comparative riskâ€adjusted mortality outcomes after primary surgery, radiotherapy, or androgenâ€deprivation therapy for localized prostate cancer. Cancer, 2010, 116, 5226-5234.	4.1	286
46	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	2.0	39
47	Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?. BJU International, 2010, 105, 1510-1513.	2.5	53
48	The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU International, 2010, 105, 1237-1241.	2.5	27
49	The â€˜CaP Calculatorâ€™: an online decision support tool for clinically localized prostate cancer. BJU International, 2010, 105, 1417-1422.	2.5	19
50	Hormonal therapy for prostate cancer: Current topics and future perspectives. International Journal of Urology, 2010, 17, 302-313.	1.0	11
51	Postoperative prostateâ€specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. International Journal of Urology, 2010, 17, 914-922.	1.0	9
52	Role of Radical Prostatectomy for High-Risk Prostate Cancer. Korean Journal of Urology, 2010, 51, 589.	1.2	2
53	The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer and Prostatic Diseases, 2010, 13, 87-93.	3.9	13
54	TMPRSS2â€"ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Modern Pathology, 2010, 23, 1325-1333.	5.5	95
56	Minimal Impact of Clinical Stage on Prostate Cancer Prognosis Among Contemporary Patients With Clinically Localized Disease. Journal of Urology, 2010, 184, 114-119.	0.4	39
57	Positive Surgical Margins at Radical Prostatectomy Predict Prostate Cancer Specific Mortality. Journal of Urology, 2010, 183, 2213-2218.	0.4	195
58	Outcomes After Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results From the SEARCH Database. Urology, 2010, 76, 695-700.	1.0	75

#	Article	IF	Citations
59	The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 171-176.	1.6	18
60	The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of relapse. Radiotherapy and Oncology, 2011, 101, 513-520.	0.6	13
61	The Percent of Positive Biopsy Cores Improves Prediction of Prostate Cancer–Specific Death in Patients Treated With Dose-Escalated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e135-e142.	0.8	18
62	Gleason Pattern 5 Is the Greatest Risk Factor for Clinical Failure and Death From Prostate Cancer After Dose-Escalated Radiation Therapy and Hormonal Ablation. International Journal of Radiation Oncology Biology Physics, 2011, 81, e351-e360.	0.8	68
64	Accuracy of the Kattan nomogram across prostate cancer risk groups. BJU International, 2011, 108, 56-60.	2.5	20
65	Perioperative, functional and oncological outcomes after open and minimally invasive prostate cancer surgery: experience from Australasia. BJU International, 2011, 107, 11-19.	2.5	25
66	Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU International, 2011, 108, 1762-1768.	2.5	6
67	Comparative analysis of three risk assessment tools in Australian patients with prostate cancer. BJU International, 2011, 108, 51-56.	2.5	19
68	COMPARATIVE ANALYSIS OF THREE RISK ASSESSMENT TOOLS IN AUSTRALIAN PATIENTS WITH PROSTATE CANCER. BJU International, 2011, 108, 56-57.	2.5	1
69	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303.	1.9	267
70	The example of CaPSURE: lessons learned from a national disease registry. World Journal of Urology, 2011, 29, 265-271.	2.2	32
71	Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer, 2011, 117, 283-289.	4.1	59
73	The CAPRA–S score. Cancer, 2011, 117, 5039-5046.	4.1	359
74	Endorectal MRI of Prostate Cancer: Incremental Prognostic Importance of Gross Locally Advanced Disease. American Journal of Roentgenology, 2011, 197, 1369-1374.	2.2	16
75	Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 1271-1276.	1.3	6
76	Pathology Update for Urologists. Prostate Cancer, 2011, 2011, 1-2.	0.6	3
77	Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 228-234.	1.6	259
78	Prognostic Factors for the Development of Biochemical Recurrence after Radical Prostatectomy. Prostate Cancer, 2011, 2011, 1-6.	0.6	15

#	ARTICLE	IF	CITATIONS
79	External Validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 747 Clinical Oncology, 2011, 41, 1259-1264.	1.3	14
80	Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy. Advances in Urology, 2012, 2012, 1-7.	1.3	7
81	Current Challenges in Development of Differentially Expressed and Prognostic Prostate Cancer Biomarkers. Prostate Cancer, 2012, 2012, 1-9.	0.6	19
82	External Validation of the Cancer of the Prostate Risk Assessment Score to Predict Biochemical Relapse after Radical Prostatectomy for Prostate Cancer in Japanese Patients. Urologia Internationalis, 2012, 89, 45-51.	1.3	6
83	Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. Health Affairs, 2012, 31, 730-740.	5.2	35
84	Percentage of Cancer Volume in Biopsy Cores Is Prognostic for Prostate Cancer Death and Overall Survival in Patients Treated With Dose-Escalated External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 940-946.	0.8	20
85	The Number of High-Risk Factors and the Risk of Prostate Cancerâ€"Specific Mortality After Brachytherapy: Implications for Treatment Selection. International Journal of Radiation Oncology Biology Physics, 2012, 82, e773-e779.	0.8	17
86	Bias Due to Missing SEER Data in D'Amico Risk Stratification of Prostate Cancer. Journal of Urology, 2012, 187, 2026-2031.	0.4	24
87	193 PROGNOSTIC SIGNIFICANCE OF POSITIVE SURGICAL MARGINS AFTER RADICAL PROSTATECTOMY AMONG PT2 AND PT3A PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.4	1
88	External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 584-589.	1.6	16
89	Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 179-190.	2.5	14
90	Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagnostic Pathology, 2012, 7, 68.	2.0	15
91	Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of highâ€risk prostate cancer. BJU International, 2012, 110, E783-8.	2.5	91
92	Treatment of Localized Prostate Cancer. , 2012, , 141-154.		0
93	An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account. PLoS ONE, 2012, 7, e45178.	2.5	33
94	Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer. Prostate, 2012, 72, 280-290.	2.3	6
95	The quantitative Gleason score improves prostate cancer risk assessment. Cancer, 2012, 118, 6046-6054.	4.1	53
96	High-Risk Prostate Cancer: From Definition to Contemporary Management. European Urology, 2012, 61, 1096-1106.	1.9	119

#	Article	IF	Citations
97	Editorial Comment to Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: Comparison with Western predictive tools using decision curve analysis. International Journal of Urology, 2012, 19, 853-854.	1.0	2
98	Outcomes in patients with Gleason score 8â€"10 prostate cancer: relation to preoperative PSA level. BJU International, 2012, 109, 1764-1769.	2.5	43
99	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU International, 2012, 110, 1714-1720.	2.5	12
100	Should we abstain from Gleason score 2â€"4 in the diagnosis of prostate cancer? Results of a German multicentre study. World Journal of Urology, 2012, 30, 97-103.	2.2	6
101	Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU International, 2013, 111, 549-558.	2.5	17
102	Predictors of Gleason score upgrading in a large African-American population. International Urology and Nephrology, 2013, 45, 1257-1262.	1.4	17
103	A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU International, 2013, 112, E67-75.	2.5	86
104	Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. International Journal of Urology, 2013, 20, 301-311.	1.0	30
105	Benign Prostate Glandular Tissue at Radical Prostatectomy Surgical Margins. Urology, 2013, 82, 154-159.	1.0	11
106	MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer. Clinical Chemistry, 2013, 59, 1595-1603.	3.2	50
107	Biomarkers in prostate cancer surveillance and screening: past, present, and future. Therapeutic Advances in Urology, 2013, 5, 318-329.	2.0	99
108	Circulating microRNAs as potential new biomarkers for prostate cancer. British Journal of Cancer, 2013, 108, 1925-1930.	6.4	130
109	Antioxidant and vitamin E transport genes and risk of highâ€grade prostate cancer and prostate cancer recurrence. Prostate, 2013, 73, 1786-1795.	2.3	21
110	Evaluation of prediction models for the staging of prostate cancer. BMC Medical Informatics and Decision Making, 2013, 13, 126.	3.0	20
111	Immediate renal transplantation after radical prostatectomy for lowâ€risk prostate cancer. Clinical Transplantation, 2013, 27, 162-167.	1.6	10
112	Prognostic value of the <scp>CAPRA</scp> clinical prediction rule: a systematic review and metaâ€analysis. BJU International, 2013, 111, 427-436.	2.5	25
113	Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 595-600.	1.6	14
114	The Impact of Clinical Stage on Prostate Cancer Survival Following Radical Prostatectomy. Journal of Urology, 2013, 189, 1707-1712.	0.4	41

#	Article	IF	Citations
115	Retrospective Evaluation Reveals That Long-term Androgen Deprivation Therapy Improves Cause-Specific and Overall Survival in the Setting of Dose-Escalated Radiation for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 64-71.	0.8	16
116	Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era. Urology, 2013, 82, 60-66.	1.0	26
117	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	1.9	95
118	Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. Drugs, 2013, 73, 1417-1430.	10.9	39
119	Results of surgery for high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 342-348.	1.8	20
120	Predicting high risk disease using serum and DNA biomarkers. Current Opinion in Urology, 2013, 23, 252-260.	1.8	10
121	Defining high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 337-341.	1.8	16
122	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU International, 2013, 111, E158-66.	2.5	61
123	Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU International, 2013, 111, E306-E309.	2.5	7
124	Validation of the prognostic grouping of the seventh edition of the tumorâ€nodesâ€metastasis classification using a largeâ€scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy. International Journal of Urology, 2013, 20, 880-888.	1.0	10
125	Radiotherapy in the management of prostate cancer after radical prostatectomy. Future Oncology, 2013, 9, 669-679.	2.4	5
126	Re-Examining Racial Disparities in Prostate Cancer Outcomes. Journal of Clinical Oncology, 2013, 31, 2979-2980.	1.6	20
127	The role of radical prostatectomy in high-risk prostate cancer. Prostate International, 2013, 1, 95-101.	2.3	19
128	Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer. Korean Journal of Urology, 2013, 54, 417.	1.2	2
129	External Validation of the Cancer of the Prostate Risk Assessment-S Score in Koreans Undergoing Radical Prostatectomy. Korean Journal of Urology, 2013, 54, 433.	1.2	11
130	Seminal Plasma as a Source of Prostate Cancer Peptide Biomarker Candidates for Detection of Indolent and Advanced Disease. PLoS ONE, 2013, 8, e67514.	2.5	43
131	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. PLoS ONE, 2014, 9, e98597.	2.5	41
132	Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): Ability to Predict Cancer Progression and Decision-Making Regarding Adjuvant Therapy after Radical Prostatectomy. Journal of Korean Medical Science, 2014, 29, 1212.	2.5	13

#	Article	IF	Citations
133	Implementation of PSA-based active surveillance in prostate cancer. Biomarkers in Medicine, 2014, 8, 747-753.	1.4	4
134	Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal of Cancer, 2014, 111, 1201-1212.	6.4	123
135	Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2014, 17, 199-205.	3.9	12
136	Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	163
137	Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer and Prostatic Diseases, 2014, 17, 246-251.	3.9	18
138	Evaluation of D'Amico criteria for low-risk prostate cancer. Scandinavian Journal of Urology, 2014, 48, 344-349.	1.0	6
139	Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer and Prostatic Diseases, 2014, 17, 57-63.	3.9	91
140	Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. Cancer, 2014, 120, 507-512.	4.1	32
141	NADiA ProsVue Prostate-specific Antigen Slope, CAPRA-S, and Prostate Cancer–specific Survival After Radical Prostatectomy. Urology, 2014, 84, 1427-1433.	1.0	3
142	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research, 2014, 20, 5302-5310.	7.0	19
143	Predictive Value of the Cancer of the Prostate Risk Assessment Score for Recurrence-Free Survival After Radical Prostatectomy in Korea: A Single-Surgeon Series. Korean Journal of Urology, 2014, 55, 321.	1.2	9
144	Current Status of Radical Prostatectomy for High-Risk Prostate Cancer. Korean Journal of Urology, 2014, 55, 629.	1.2	9
145	The status of surgery in the management of high-risk prostate cancer. Nature Reviews Urology, 2014, 11, 342-351.	3.8	34
146	Predicting the risk of bone metastasis in prostate cancer. Cancer Treatment Reviews, 2014, 40, 3-11.	7.7	53
147	Prevalence of the <i><scp>HOXB13</scp></i>â€…<scp>G84E</scp> prostate cancer risk allele in men treated with radical prostatectomy. BJU International, 2014, 113, 830-835.	2.5	21
148	Can we improve the definition of highâ€risk, hormone naÃ¯ve, nonâ€metastatic prostate cancer?. BJU International, 2014, 113, 189-199.	2.5	11
149	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. European Urology, 2014, 65, 546-551.	1.9	81
150	High-risk prostate cancer—classification and therapy. Nature Reviews Clinical Oncology, 2014, 11, 308-323.	27.6	340

#	ARTICLE	IF	CITATIONS
151	The time is ripe to redefine high‐risk prostate cancer?. BJU International, 2014, 113, 181-181.	2.5	0
152	National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United States. Urology Practice, 2014, 1, 198-204.	0.5	4
153	Analysis of the Cancer of the Prostate Risk Assessment to Predict for Biochemical Failure After External Beam Radiotherapy or Prostate Seed Brachytherapy. Urology, 2014, 84, 629-633.	1.0	12
154	The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5ng/ml. Cancer Epidemiology, 2014, 38, 613-618.	1.9	4
155	Recent Trends in the Initial Therapy for Newly Diagnosed Prostate Cancer in Japan. Japanese Journal of Clinical Oncology, 2014, 44, 969-981.	1.3	41
156	Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated <scp>P</scp>artin <scp>T</scp>ables vs a <scp>E</scp>uropean predictive nomogram for organ‐confined disease in prostate cancer. BJU International, 2014, 113, 878-886.	2.5	17
157	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Human Pathology, 2014, 45, 2006-2013.	2.0	5
158	The Ongoing Need for Improved Risk Stratification and Monitoring for Those on Active Surveillance for Early Stage Prostate Cancer. European Urology, 2014, 65, 1032-1033.	1.9	7
159	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	1.9	553
160	Usefulness of J-CAPRA Score for High-risk Prostate Cancer Patients Treated with Carbon Ion Radiotherapy Plus Androgen Deprivation Therapy. Japanese Journal of Clinical Oncology, 2014, 44, 360-365.	1.3	3
161	Randomized Trials for Adjuvant Radiotherapy. Medical Radiology, 2014, , 231-242.	0.1	0
162	Expectant management for men with early stage prostate cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 264-282.	329.8	59
163	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1351-1358.	4.9	17
164	Improving Prediction of Prostate Cancer Recurrence using Chemical Imaging. Scientific Reports, 2015, 5, 8758.	3.3	51
166	The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases. EJNMMI Research, 2015, 5, 77.	2.5	6
167	Elevated Serum MicroRNA Levels Associate with Absence of High-Grade Prostate Cancer in a Retrospective Cohort. PLoS ONE, 2015, 10, e0124245.	2.5	65
168	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. Journal of Urology, 2015, 194, 977-982.	0.4	39
169	Prostate Cancer Risk Estimation Tool Use by Members of the American Urological Association: A Survey Based Study. Journal of Urology, 2015, 193, 1933-1937.	0.4	4

#	Article	IF	Citations
170	QPI for prostate cancer diagnosis: quantitative separation of Gleason grades 3 and 4. Proceedings of SPIE, 2015, , .	0.8	0
171	Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e1-384.e8.	1.6	5
172	External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort. Journal of Urology, 2015, 193, 1970-1975.	0.4	50
173	Primary Radical Therapy Selection in High-risk Non-metastatic Prostate Cancer. Clinical Oncology, 2015, 27, 136-144.	1.4	9
174	Current Use of Imaging after Primary Treatment of Prostate Cancer. Journal of Urology, 2015, 194, 98-104.	0.4	4
175	Is clinical stage T2c prostate cancer an intermediate€•or high€•risk disease?. Cancer, 2015, 121, 1414-1421.	4.1	12
176	Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. European Urology, 2015, 68, 480-486.	1.9	42
177	Report of a Simplified Frailty Score Predictive of Short-Term Postoperative Morbidity and Mortality. Journal of the American College of Surgeons, 2015, 220, 904-911.e1.	0.5	87
178	The Histogram Analysis of Diffusion-Weighted Intravoxel Incoherent Motion (IVIM) Imaging for Differentiating the Gleason grade of Prostate Cancer. European Radiology, 2015, 25, 994-1004.	4.5	117
179	A urine-based methylation signature for risk stratification within low-risk prostate cancer. British Journal of Cancer, 2015, 112, 802-808.	6.4	16
180	Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. European Urology, 2015, 68, 458-463.	1.9	49
181	Cutaneous Angiosarcoma of Head and Neck: A New Predictive Score for Locoregional Metastasis. Translational Oncology, 2015, 8, 169-175.	3.7	16
182	Patterns of Repeat Prostate Biopsy in Contemporary Clinical Practice. Journal of Urology, 2015, 193, 1178-1184.	0.4	75
183	Comparison of MR/Ultrasound Fusion€"Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	7.4	1,267
184	Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology, 2015, 33, 1078-1085.	1.6	108
185	Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 70.e9-70.e14.	1.6	4
186	Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer, 2015, 113, 382-389.	6.4	126
187	Prebiopsy MRI and MRI-ultrasound Fusion€"targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. Urology, 2015, 86, 1192-1199.	1.0	71

#	ARTICLE	IF	CITATIONS
188	Adjuvant vs. salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 451-455.	1.6	4
189	Imaging and evaluation of patients with high-risk prostate cancer. Nature Reviews Urology, 2015, 12, 617-628.	3.8	34
190	Radiotherapy in Prostate Cancer. Medical Radiology, 2015, , .	0.1	6
191	Do prostate cancer nomograms give accurate information when applied to European patients?. Scandinavian Journal of Urology, 2015, 49, 16-24.	1.0	17
192	Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate, 2015, 75, 60-69.	2.3	31
193	Advances in Image-Guided Urologic Surgery. , 2015, , .		3
194	Active surveillance for low-risk prostate cancer: diversity of practice across Europe. Irish Journal of Medical Science, 2015, 184, 305-311.	1.5	6
195	Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. European Urology, 2015, 67, 326-333.	1.9	178
196	Contemporary Management of Prostate Cancer. F1000Research, 2016, 5, 179.	1.6	9
197	Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era. Canadian Urological Association Journal, 2016, 10, 17.	0.6	11
198	Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer. Ecancermedicalscience, 2016, 10, 671.	1.1	1
199	Preoperative Risk Assessment. , 2016, , 227-233.		0
200	External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score for Prediction of Disease Recurrence after Radical Prostatectomy. Advances in Medicine, 2016, 2016, 1-5.	0.8	0
201	Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS Medicine, 2016, 13, e1002063.	8.4	51
202	Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate, 2016, 76, 1239-1256.	2.3	20
203	Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 173-180.	1.3	9
204	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	2.5	7
205	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.7	6

#	Article	IF	Citations
206	Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 727-733.	0.4	4
207	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scandinavian Journal of Urology, 2016, 50, 255-259.	1.0	6
208	High-risk prostate cancer: the role of surgical management. Critical Reviews in Oncology/Hematology, 2016, 102, 135-143.	4.4	13
209	Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 430.e17-430.e25.	1.6	8
210	Management and treatment of men affected by metastatic prostate cancer: evidence‐based recommendations for practice. International Journal of Urological Nursing, 2016, 10, 44-55.	0.2	6
211	MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer. Cellular Physiology and Biochemistry, 2016, 39, 1111-1117.	1.6	26
212	The role of MRI in prostate cancer diagnosis and management. Future Oncology, 2016, 12, 2431-2443.	2.4	22
213	Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncology, 2016, 12, 2417-2430.	2.4	20
214	Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 416.e15-416.e21.	1.6	17
215	Is Surgery Still Necessary for Prostate Cancer?. , 2016, , 235-243.		0
216	Management of Locally Advanced (Nonmetastatic) Prostate Cancer. , 2016, , 467-477.		0
217	PREDICT: model for prediction of survival in localized prostate cancer. World Journal of Urology, 2016, 34, 789-795.	2.2	10
218	Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes. Journal of Radiation Research, 2016, 57, 280-287.	1.6	10
219	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. Pharmaceutical Research, 2016, 33, 2459-2469.	3.5	8
220	Prostate Cancer Registries: Current Status and Future Directions. European Urology, 2016, 69, 998-1012.	1.9	56
221	Extended lymphadenectomy: A critical review. European Urology Supplements, 2016, 15, 33-33c.	0.1	0
222	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 254-262.	0.8	31
223	Impact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapy. European Journal of Radiology, 2016, 85, 764-770.	2.6	12

#	ARTICLE	IF	CITATIONS
224	Clinical and Pathologic Staging of Prostate Cancer. , 2016, , 353-360.		0
225	Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Review of Anticancer Therapy, 2016, 16, 433-440.	2.4	26
227	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology, 2016, 89, 69-75.	1.0	43
228	New Genetic Markers for Prostate Cancer. Urologic Clinics of North America, 2016, 43, 7-15.	1.8	12
229	Molecular Profiles of Prostate Cancer: To Treat or Not to Treat. Annual Review of Medicine, 2016, 67, 119-135.	12.2	15
230	Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. International Journal of Clinical Oncology, 2016, 21, 595-600.	2.2	15
231	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	2.5	45
232	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.4	122
233	Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models. European Urology, 2016, 69, 1038-1043.	1.9	13
234	Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer. Journal of Urology, 2016, 195, 80-87.	0.4	27
235	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 329-332.	1.9	8
236	End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 203-209.	3.9	4
237	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2017, 197, 1026-1033.	0.4	13
238	Biomarkers for Prostate Biopsy and Risk Stratification of Patients with Newly Diagnosed Prostate Cancer. Urology Practice, 2017, 4, 315-321.	0.5	7
239	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	1.9	179
240	Convolutional neural networks for prostate cancer recurrence prediction. Proceedings of SPIE, 2017, , .	0.8	18
241	Improving the evaluation and diagnosis of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 191-197.	1.8	11
242	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology, 2017, 72, 509-518.	1.9	26

#	Article	IF	Citations
243	Management of intermediate-risk prostate cancer with active surveillance. Current Opinion in Urology, 2017, 27, 231-237.	1.8	8
244	Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients. Urology, 2017, 102, 73-78.	1.0	19
245	Prognostic utility of biopsyâ€derived cell cycle progression score in patients with National Comprehensive Cancer Network lowâ€risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU International, 2017, 120, 808-814.	2.5	48
246	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	1.9	79
247	Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series. Prostate International, 2017, 5, 53-58.	2.3	5
248	An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiation Oncology, 2017, 12, 56.	2.7	13
249	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 982-995.	0.8	56
250	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
251	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	1.9	14
252	Impact of treatment on progression to castrationâ€resistance, metastases, and death in men with localized highâ€grade prostate cancer. Cancer Medicine, 2017, 6, 163-172.	2.8	16
253	Whom to Treat. Urologic Clinics of North America, 2017, 44, 547-555.	1.8	5
254	Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score. Oncology Research and Treatment, 2017, 40, 508-514.	1.2	3
255	Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 663.e9-663.e14.	1.6	10
256	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer, 2017, 123, 4574-4582.	4.1	36
257	Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e1-605.e8.	1.6	20
258	The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. Scandinavian Journal of Urology, 2017, 51, 450-456.	1.0	18
259	High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?. Scientific Reports, 2017, 7, 16308.	3.3	15
260	Effect of Time-of-Flight and Regularized Reconstructions on Quantitative Measurements and Qualitative Assessments in Newly Diagnosed Prostate Cancer With ^{18}F-Fluorocholine Dual Time Point PET/MRI. Molecular Imaging, 2017, 16, 153601211773670.	1.4	1

#	ARTICLE	IF	CITATIONS
261	The Diagnosis and Treatment of Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2532.	7.4	959
262	Prediction models for prostate cancer outcomes. Current Opinion in Urology, 2017, 27, 469-474.	1.8	4
263	Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer. BMC Urology, 2017, 17, 39.	1.4	10
264	Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer. World Journal of Surgical Oncology, 2017, 15, 50.	1.9	6
265	What is the best way not to treat prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 42-50.	1.6	13
266	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. Journal of Pathology, 2017, 241, 173-182.	4.5	36
267	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clinical Genitourinary Cancer, 2017, 15, 93-99.	1.9	1
268	Tumor Volume and Clinical Failure in Highâ€Risk Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 3-9.	2.3	8
269	Predictive models in cancer management: A guide for clinicians. Journal of the Royal College of Surgeons of Edinburgh, 2017, 15, 93-97.	1.8	9
270	18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology, 2017, 282, 429-436.	7.3	15
271	Clinicopathological, functional, and immediate oncologic outcome assessment in men agedâ‰¤50 years with prostate cancer after robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e17-30.e24.	1.6	12
272	MR-based prognostic nomogram for prostate cancer after radical prostatectomy. Journal of Magnetic Resonance Imaging, 2017, 45, 586-596.	3.4	21
273	The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. European Urology, 2017, 71, 705-709.	1.9	72
274	Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center. Urology, 2017, 100, 169-174.	1.0	0
275	Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. Journal of Magnetic Resonance Imaging, 2017, 45, 125-131.	3.4	38
276	The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy. European Urology, 2017, 71, 701-704.	1.9	94
277	The Surgical Management of Prostate Cancer. Seminars in Oncology, 2017, 44, 347-357.	2.2	60
278	Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiologia Brasileira, 2017, 50, 299-307.	0.7	11

#	ARTICLE	IF	CITATIONS
279	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 94.	0.6	0
280	Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings. BMC Cancer, 2017, 17, 537.	2.6	3
281	Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. BMC Urology, 2017, 17, 60.	1.4	5
282	Active Surveillance in Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1898-1904.	1.6	46
283	Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a radiologic learning curve. World Journal of Urology, 2018, 36, 1409-1415.	2.2	16
284	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 310.e7-310.e13.	1.6	19
285	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	1.9	30
286	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Radiologic Clinics of North America, 2018, 56, 239-250.	1.8	13
287	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology, 2018, 73, 502-511.	1.9	37
288	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	9.4	107
289	The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Medicine, 2018, 16, 31.	5.5	36
290	Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 2018, 10, .	12.4	124
291	Molecular correlates of intermediate- and high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 368-374.	1.6	5
292	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. European Urology, 2018, 73, 215-223.	1.9	45
293	The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Nuclear Medicine, 2018, 59, 204-209.	5.0	25
294	Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030619.	6.2	2
295	Baseline and longitudinal plasma caveolinâ€‘1 level as a biomarker in active surveillance for earlyâ€‘stage prostate cancer. BJU International, 2018, 121, 69-76.	2.5	10
296	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182.	27.6	7

#	ARTICLE	IF	CITATIONS
297	Optimising preoperative risk stratification tools for prostate cancer using mpMRI. European Radiology, 2018, 28, 1016-1026.	4.5	18
298	Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer. International Journal of Clinical Oncology, 2018, 23, 361-367.	2.2	0
299	Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREâ„¢). Prostate, 2018, 78, 32-39.	2.3	22
300	Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-15.	3.0	13
301	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
302	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	1.6	162
303	Optimization of Risk Stratification in Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 528-532.	1.6	4
304	Preoperative PROSTATE scoring system: a potential predictive tool for the risk of biochemical recurrence after radical prostatectomy. Cancer Management and Research, 2018, Volume 10, 4671-4677.	1.9	1
305	Heterogeneity of risk within Gleason 4â€°+â€°4, 4â€°+â€°5 and 5â€°+â€°4 prostate cancer. Scandinavian Journal of Urology, 2018, 52, 340-348.	1.0	6
306	68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. Nuclear Medicine Communications, 2018, 39, 871-880.	1.1	5
307	The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e36.	2.5	1
308	Predictive value of combined analysis of proâ€¹scp›NPY‹/scp› and ‹scp›ERG‹/scp› in localized prostate cancer. Apmis, 2018, 126, 804-813.	2.0	12
310	Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores. Future Oncology, 2018, 14, 1469-1476.	2.4	0
312	Tissue proteomics studies in the investigation of prostate cancer. Expert Review of Proteomics, 2018, 15, 593-611.	3.0	8
313	Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology, 2018, 29, 1814-1821.	1.2	35
314	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	3.8	78
315	Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies. World Journal of Surgical Oncology, 2018, 16, 124.	1.9	50
316	Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy. American Journal of Roentgenology, 2018, 211, 805-811.	2.2	1

#	ARTICLE	IF	CITATIONS
317	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Urologic Clinics of North America, 2018, 45, 455-466.	1.8	9
318	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Urologia Internationalis, 2018, 101, 56-64.	1.3	17
319	A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. Health and Quality of Life Outcomes, 2018, 16, 40.	2.4	8
320	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.6	10
321	Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. Future Oncology, 2018, 14, 3073-3083.	2.4	4
322	Specimen Provenance Testing Identifies Contamination That Affects Molecular Prognostic Assay Results in Prostate Cancer Biopsy Specimens. Urology, 2018, 115, 87-91.	1.0	0
323	Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings. Asian Journal of Urology, 2019, 6, 321-329.	1.2	7
324	The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 574.e1-574.e9.	1.6	3
325	Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging. Frontiers in Oncology, 2019, 9, 572.	2.8	11
326	The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status. Prostate Cancer, 2019, 2019, 1-14.	0.6	8
327	Use of health-related indices and classification methods in medical data. , 2019, , 31-66.		3
328	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. Cancers, 2019, 11, 1603.	3.7	28
329	Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Personalized Medicine, 2019, 16, 491-499.	1.5	9
330	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. Journal of Clinical Pathology, 2019, 72, 696-704.	2.0	5
331	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nuclear Medicine and Biology, 2019, 68-69, 66-79.	0.6	19
332	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	2.2	4
333	Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review. BMJ Open, 2019, 9, e029149.	1.9	15
334	Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. Clinical Genitourinary Cancer, 2019, 17, e745-e750.	1.9	7

#	ARTICLE	IF	CITATIONS
335	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics, 2019, 9, 2812-2826.	10.0	20
336	Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, e645-e649.	1.9	4
337	Biochemical recurrenceâ€free conditional probability after radical prostatectomy: A dynamic prognosis. International Journal of Urology, 2019, 26, 725-730.	1.0	4
338	Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. Abdominal Radiology, 2019, 44, 2864-2873.	2.1	8
339	Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies . Research and Reports in Urology, 2019, Volume 11, 29-42.	1.0	8
340	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 1025.	4.1	4
341	Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. PLoS Medicine, 2019, 16, e1002758.	8.4	56
342	epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. JCO Precision Oncology, 2019, 2019, 1-18.	3.0	27
343	NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6â€¹³C₂]glucose. Magnetic Resonance in Medicine, 2019, 82, 566-576.	3.0	7
344	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1642-1651.	2.5	13
345	Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1917-1925.	2.5	20
346	Why we should take care of the competing risk bias in survival analysis: A phase II trial on the toxicity profile of radiotherapy for prostate cancer. Reports of Practical Oncology and Radiotherapy, 2019, 24, 511-519.	0.6	6
347	The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer. Current Urology, 2019, 13, 25-30.	0.6	5
348	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Frontiers in Oncology, 2019, 9, 1287.	2.8	22
349	Active surveillance for intermediate-risk prostate cancer. Current Opinion in Urology, 2019, 29, 605-611.	1.8	12
350	Nomograms in urologic oncology, advantages and disadvantages. Current Opinion in Urology, 2019, 29, 42-51.	1.8	27
351	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology, 2019, 125, 154-162.	1.0	20
352	Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e1-181.e6.	1.6	18

#	Article	IF	Citations
353	Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology, 2019, 74, 135-145.	2.9	114
354	Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. European Urology, 2019, 75, 515-522.	1.9	22
355	Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA). BMC Medical Informatics and Decision Making, 2019, 19, 2.	3.0	20
356	TNM clinical staging of prostate cancer: issues and solutions. BJU International, 2019, 123, 382-384.	2.5	10
357	askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men. European Urology, 2019, 75, 901-907.	1.9	32
358	Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification. International Journal of Urology, 2019, 26, 62-68.	1.0	8
359	Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU International, 2019, 123, 846-853.	2.5	21
360	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8â€"10 Prostate Cancers Identifies Very Highâ€"risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus, 2019, 5, 998-1006.	3.1	25
361	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	3.1	5
362	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 30-39.	2.8	3
363	Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology, 2020, 77, 180-188.	1.9	87
364	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate Cancer and Prostatic Diseases, 2020, 23, 102-107.	3.9	26
365	Preoperative Prediction of Extracapsular Extension: Radiomics Signature Based on Magnetic Resonance Imaging to Stage Prostate Cancer. Molecular Imaging and Biology, 2020, 22, 711-721.	2.6	34
366	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1474-1494.	1.6	141
367	Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 lowÂdose rate brachytherapy monotherapy. Brachytherapy, 2020, 19, 43-50.	0.5	15
368	Should all prostate needle biopsy Gleason score 4â€"+â€"4â€"=â€"8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e1-78.e6.	1.6	6
369	10-Year Clinical Experience With 18F-Choline PET/CT. Clinical Nuclear Medicine, 2020, 45, 594-603.	1.3	6
370	Advances in Prognostic Methylation Biomarkers for Prostate Cancer. Cancers, 2020, 12, 2993.	3.7	16

#	Article	IF	Citations
371	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
372	A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence. BMC Cancer, 2020, 20, 953.	2.6	2
373	Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. European Urology Oncology, 2020, , .	5.4	7
374	Prostate cancer biology & genomics. Translational Andrology and Urology, 2020, 9, 1481-1491.	1.4	4
375	Surgical management of high-risk, localized prostate cancer. Nature Reviews Urology, 2020, 17, 679-690.	3.8	20
376	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. Tumori, 2021, 107, 030089162094395.	1.1	2
377	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. International Journal of Molecular Sciences, 2020, 21, 7812.	4.1	8
378	Modified Jâ€CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy. Cancer Medicine, 2020, 9, 9346-9352.	2.8	3
379	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imagingâ€"targeted Biopsy. European Urology Oncology, 2020, 3, 739-747.	5.4	31
380	Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate, 2020, 80, 1421-1428.	2.3	1
381	Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin. Prostate International, 2020, 8, 178-184.	2.3	6
382	Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression. Cancers, 2020, 12, 1268.	3.7	8
383	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e241-e252.	3.8	16
384	Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era. PLoS ONE, 2020, 15, e0234391.	2.5	0
385	Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Medicine, 2020, 18, 139.	5.5	10
386	Radiomics Based on Multiparametric Magnetic Resonance Imaging to Predict Extraprostatic Extension of Prostate Cancer. Frontiers in Oncology, 2020, 10, 940.	2.8	28
387	Prostate cancer: more effective use of underutilized postoperative radiation therapy. Expert Review of Anticancer Therapy, 2020, 20, 241-249.	2.4	1
388	Deep learning-based survival prediction for multiple cancer types using histopathology images. PLoS ONE, 2020, 15, e0233678.	2.5	143

#	ARTICLE	IF	CITATIONS
389	A Machine Learning Approach to Predict an Early Biochemical Recurrence after a Radical Prostatectomy. Applied Sciences (Switzerland), 2020, 10, 3854.	2.5	1
390	The relationship between pre‐radiation therapy testosterone levels and prostate cancer aggressiveness. Andrologia, 2020, 52, e13731.	2.1	1
391	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS ONE, 2020, 15, e0235779.	2.5	8
392	Differences in risk factors for biochemical recurrence after radical prostatectomy stratified by the degree of obesity: Focused on surgical methods. Scientific Reports, 2020, 10, 10157.	3.3	3
393	Neoadjuvant Approaches Prior To Radical Prostatectomy. Cancer Journal (Sudbury, Mass), 2020, 26, 2-12.	2.0	5
394	Prostate MRI: staging and decision-making. Abdominal Radiology, 2020, 45, 2143-2153.	2.1	8
395	Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?. Radiology Imaging Cancer, 2020, 2, e190071.	1.6	17
396	High spatiotemporal resolution dynamic contrast-enhanced MRI improves the image-based discrimination of histopathology risk groups of peripheral zone prostate cancer: a supervised machine learning approach. European Radiology, 2020, 30, 4828-4837.	4.5	4
397	Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance. Cancer, 2020, 126, 2986-2990.	4.1	20
398	A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men. Urology, 2020, 142, 166-173.	1.0	10
399	Histological comparison between predictive value of preoperative 3‐T multiparametric MRI and [68]Ga‐PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 71-79.	2.5	45
400	Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system. Cancer Medicine, 2021, 10, 87-97.	2.8	4
401	Influence of pelvic lymph node dissection and node‐positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. Prostate, 2021, 81, 102-108.	2.3	6
402	Does radical prostatectomy result in lower urinary tract symptom improvement in high-risk and locally advanced prostate cancer? A Single-center experience. Urologia, 2021, 88, 110-114.	0.7	1
403	Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 366.e19-366.e28.	1.6	1
404	A novel tool to predict functional outcomes after robot‐assisted radical prostatectomy and the value of additional surgery for incontinence. BJU International, 2021, 127, 575-584.	2.5	13
405	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	3.7	3
406	Risk stratification tools in prostate cancer, where do we stand?. Translational Andrology and Urology, 2021, 10, 12-18.	1.4	4

#	Article	IF	Citations
407	The Management of Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 3-23.	0.1	0
408	MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. Computational and Structural Biotechnology Journal, 2021, 19, 4941-4953.	4.1	9
409	[18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA <â€‰0.5Âng/mL. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2038-2046.	6.4	22
410	Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. Cancers, 2021, 13, 628.	3.7	7
411	Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients. Translational Andrology and Urology, 2021, 10, 584-593.	1.4	0
412	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	30.5	434
413	Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. Frontiers in Oncology, 2020, 10, 607923.	2.8	7
414	Morbidity and All-Cause Mortality Following Radical Prostatectomy Compared with Observation for Localized Prostate Cancer in Chinese Men: A Non-Randomized Retrospective Study. Medical Science Monitor, 2021, 27, e928596.	1.1	0
415	Nomograms in Urologic Oncology: Lights and Shadows. Journal of Clinical Medicine, 2021, 10, 980.	2.4	13
416	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. Journal of Urology, 2021, 205, 1055-1062.	0.4	12
418	Monotonic Functions Method and Its Application to Staging of Patients with Prostate Cancer According to Pretreatment Data. Applied Sciences (Switzerland), 2021, 11, 3836.	2.5	0
419	A 2021 update on cancer image analytics with deep learning. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2021, 11, e1410.	6.8	10
420	Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 646073.	2.8	3
421	External Validation of the Extraprostatic Extension Grade on MRI and Its Incremental Value to Clinical Models for Assessing Extraprostatic Cancer. Frontiers in Oncology, 2021, 11, 655093.	2.8	7
422	Evaluation of predictive model performance of an existing model in the presence of missing data. Statistics in Medicine, 2021, 40, 3477-3498.	1.6	2
423	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e11-785.e17.	1.6	6
424	Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre. European Urology Open Science, 2021, 27, 43-52.	0.4	12
425	The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy. BMC Urology, 2021, 21, 82.	1.4	3

#	Article	IF	Citations
426	The effect of risk factors on surgical and oncological results in highâ€risk prostate cancer: A multicentre study of the urooncology society, Turkey. International Journal of Clinical Practice, 2021, 75, e14281.	1.7	1
427	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	2.2	3
428	Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. Journal of Clinical Pathology, 2021, 74, 429-434.	2.0	19
429	Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice. International Journal of Molecular Sciences, 2021, 22, 6266.	4.1	10
430	The presence of nonâ€hepatic malignancy and its implication in pursuing liver transplantation. Clinical Transplantation, 2021, 35, e14410.	1.6	0
431	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate, 2021, 81, 1009-1017.	2.3	2
432	Investigation of Neural Microenvironment in Prostate Cancer in Context of Neural Density, Perineural Invasion, and Neuroendocrine Profile of Tumors. Frontiers in Oncology, 2021, 11, 710899.	2.8	15
433	Comparison of treatment results for patients with high-risk prostate cancer according to the EAU and NCCN criteria. Onkourologiya, 2021, 17, 54-61.	0.3	1
434	Evaluation of four preâ€operative models for prediction of biochemical recurrence after radical prostatectomy in localised prostate cancer. International Journal of Clinical Practice, 2021, 75, e14682.	1.7	3
435	Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of aÂsingle-arm phaseÂII toxicity-oriented trial. Strahlentherapie Und Onkologie, 2021, 197, 1001-1009.	2.0	1
436	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory <scp>T</scp> cells and macrophages as adverse prognostic factors. Journal of Pathology, 2021, 255, 155-165.	4.5	36
437	Active surveillance for intermediateâ€risk prostate cancer in African American and nonâ€Hispanic White men. Cancer, 2021, 127, 4403-4412.	4.1	3
438	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	2.1	0
439	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. European Urology, 2022, 81, 193-203.	1.9	30
440	Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. Cancer Reports, 2021, , e1535.	1.4	2
441	Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT. Frontiers in Oncology, 2021, 11, 745530.	2.8	3
442	Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. European Urology, 2021, 80, 400-404.	1.9	4
443	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. European Urology Oncology, 2022, 5, 537-543.	5.4	13

#	ARTICLE	IF	CITATIONS
444	Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer. Abdominal Radiology, 2021, 46, 2751-2759.	2.1	13
445	Nomograms in Prostate Cancer. , 2013, , 581-592.		1
446	Nomograms for Prostate Cancer. , 2009, , 117-180.		1
447	Prostate Cancer Surveillance Counterpoint: USA. , 2013, , 411-420.		1
448	Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. Abdominal Radiology, 2020, 45, 3882-3895.	2.1	11
449	Association of High miR-182 Levels with Low-Risk Prostate Cancer. American Journal of Pathology, 2019, 189, 911-923.	3.8	14
451	Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian Journal of Andrology, 2012, 14, 355-360.	1.6	23
452	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1222-1228.	0.4	30
453	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 278-283.	3.8	2
454	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncology Practice, 2020, 16, 340-343.	2.9	8
455	A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. PLoS ONE, 2015, 10, e0118745.	2.5	27
456	Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model. PLoS ONE, 2016, 11, e0155856.	2.5	45
457	Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS ONE, 2017, 12, e0178362.	2.5	4
458	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS ONE, 2017, 12, e0185535.	2.5	22
459	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 278-283.	3.8	3
460	An imaging-based approach predicts clinical outcomes in prostate cancer through a novel support vector machine classification. Oncotarget, 2016, 7, 78140-78151.	1.8	40
461	YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. Oncotarget, 2015, 6, 7470-7480.	1.8	23
462	The role of additional standard biopsy in the MRI-targeted biopsy era. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 637-639.	3.9	12

#	ARTICLE	IF	CITATIONS
463	Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3375-3381.	1.2	4
464	Active Surveillance or Active Treatment in Localized Prostate Cancer?. Deutsches A&#x0308;rzteblatt International, 2009, 106, 371-6.	0.9	19
465	Assessment of biochemical recurrence of prostate cancer (Review). International Journal of Oncology, 2019, 55, 1194-1212.	3.3	14
466	Current clinical challenges in prostate cancer. Translational Andrology and Urology, 2013, 2, 122-36.	1.4	34
467	Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. Asian Journal of Andrology, 2018, 20, 56.	1.6	6
468	Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian Journal of Urology, 2019, 35, 6.	0.6	23
469	Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry. Cancer Research and Treatment, 2018, 50, 88-94.	3.0	4
470	Evaluation of Biochemical Recurrence-free Survival after Radical Prostatectomy by Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) Score. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2527-2530.	1.2	9
471	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	6.0	217
472	Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications. Molecular and Cellular Biochemistry, 2022, 477, 213-223.	3.1	0
473	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	9
475	The Art and Science of Risk Stratification in Localized Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2007, 3, 101-105.	0.1	0
476	Nomograms as Predictive Tools for Prostate Cancer Patients Who Had Radical Prostatectomy. Open Journal of Urology, 2011, 01, 37-47.	0.1	0
477	Treatment of Locally Advanced Prostate Cancer. , 2012, , 2903-2920.e5.		5
478	Early Detection, Diagnosis, and Staging of Prostate Cancer. , 2012, , 2763-2770.e7.		2
479	Predicting High-Risk Disease Using Serum and DNA Biomarkers. , 2012, , 35-54.		0
480	The Future of Active Surveillance. , 2012, , 187-199.		0
481	Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer. , 2013, , 593-605.		0

#	ARTICLE	IF	CITATIONS
482	External Beam Radiotherapy for Low-Risk Prostate Cancer. , 2013, , 709-717.		0
483	Multiparametric Magnetic Resonance Imaging for Prostate Cancer. , 2015, , 141-166.		0
484	Nomograms for Prostate Cancer Decision Making. , 2015, , 93-111.		0
485	The utility of provincial AS guidelines. Canadian Urological Association Journal, 2015, 9, 372.	0.6	0
486	Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRAâ€"Should Risk Be Redefined?. , 2016, , 33-52.		0
487	Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases. , 2017, , 33-45.		0
488	Utilizing Biopsy-Based Genomic Assays to Risk-Stratify Patients. Current Clinical Urology, 2017, , 115-128.	0.0	0
489	Evaluation and Treatment for High-Risk Prostate Cancer. , 2018, , 135-156.		0
490	Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer. Open Journal of Urology, 2018, 08, 248-256.	0.1	0
491	Risk Assessment Among Patients Receiving Primary ADT for Prostate Cancer. , 2018, , 13-18.		0
492	Robot-assisted laparoscopic radical prostatectomy. Urology Herald, 2019, 6, 67-76.	0.4	0
493	Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget, 2019, 10, 1870-1871.	1.8	0
494	A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients. Translational Andrology and Urology, 2020, 9, 2572-2586.	1.4	8
495	Some ways of improvement of detection of hormone-naive non-metastatic high-risk prostate cancer. Urology, 2020, 24, .	0.1	0
496	Monitoring and Managing Men Following Initial Treatment of Prostate Cancer. , 2021, , 21-28.		0
497	Predictive models for newly diagnosed prostate cancer patients. Reviews in Urology, 2009, 11, 117-26.	0.9	21
498	Perineural invasion is an independent predictor of biochemical recurrence of prostate cancer after local treatment: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 13267-74.	1.3	12
499	Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 22319-27.	1.3	7

#	Article	IF	Citations
500	Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2017, 17, 1-75.	1.8	10
501	Caring for Patients With Prostate Cancer Who Are BRCA Positive. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 46S-51S.	0.6	0
502	Predicting Cancer-Specific Survival Among Patients With Prostate Cancer After Radical Prostatectomy Based on the Competing Risk Model: Population-Based Study. Frontiers in Surgery, 2021, 8, 770169.	1.4	3
503	Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clinical Epidemiology, 2022, Volume 14, 59-70.	3.0	2
505	The Dilemma of Misclassification Rates in Senior Patients With Prostate Cancer, Who Were Treated With Robot-Assisted Radical Prostatectomy: Implications for Patient Counseling and Diagnostics. Frontiers in Surgery, 2022, 9, 838477.	1.4	1
506	Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction. Cancer Medicine, 2022, , .	2.8	1
507	Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncology, 2022, 8, 687.	7.1	20
508	Active surveillance in favorable intermediate risk prostate cancer. Current Opinion in Oncology, 2022, Publish Ahead of Print, .	2.4	2
509	The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2022, 25, 344-350.	3.9	9
510	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	2.0	6
511	Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer. Biomarkers in Medicine, 2022, 16, 449-459.	1.4	1
512	Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. Nature Communications, 2021, 12, 7292.	12.8	15
513	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers, 2022, 14, 1623.	3.7	5
514	Establishment of Prognostic Nomograms for Early-Onset Prostate Cancer Patients: A SEER Database Analysis. Journal of Investigative Surgery, 2022, , 1-10.	1.3	1
515	Personalized Medicine in Localized Prostate Cancer: Are We There Yet?. International Journal of Radiation Oncology Biology Physics, 2022, 113, 77-79.	0.8	1
516	Gleason Grading of Prostate Cancer. , 0, , 60-76.		0
518	ProstatectomÃa Radical LaparoscÃ³pica, Nuestra Experiencia.. , 2018, 6, 25-28.		0
519	PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancerâ€"A Prospective Study of Men with 3 Year Follow Up. Cancers, 2022, 14, 2717.	3.7	6

#	Article	IF	Citations
520	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	2.3	3
521	Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification. Modern Pathology, 2022, 35, 1695-1701.	5.5	5
522	Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with ProlarisÂ® testing. BJUI Compass, 2022, 3, 458-465.	1.3	1
523	Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up. Cancers, 2022, 14, 3606.	3.7	1
524	Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy. Cancers, 2022, 14, 3966.	3.7	6
525	Different predictive values of microvessel density for biochemical recurrence among different <scp>PCa</scp> populations: A systematic review and metaâ€analysis. Cancer Medicine, 0, , .	2.8	1
526	Improving multiparametric <scp>MR</scp>â€<scp>transrectal ultrasound</scp> guided fusion prostate biopsies with hyperpolarized <scp>¹³C</scp>Âpyruvate metabolic imaging: A technical development study. Magnetic Resonance in Medicine, 2022, 88, 2609-2620.	3.0	4
528	Active Observation of Biochemical Recurrence without Treatment following Radical Prostatectomy: Long-Term Analysis of Outcomes. Cancers, 2022, 14, 4078.	3.7	1
529	Added value of shear-wave elastography in the prediction of extracapsular extension and seminal vesicle invasion before radical prostatectomy. Asian Journal of Andrology, 2022, .	1.6	1
530	Radiogenomics influence on the future of prostate cancer risk stratification. Therapeutic Advances in Urology, 2022, 14, 175628722211253.	2.0	3
531	Prostat biyopsi ve radikal prostatektomide Gleason skor konkordansÄ±nÄ±n deÄŸerlendirilmesi. Cukurova Anestezi Ve Cerrahi Bilimler Dergisi, 2022, 5, 274-279.	0.0	0
532	Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. Journal of the National Cancer Institute, 2022, 114, 1656-1664.	6.3	11
534	Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated with Dose-Escalated Radiotherapy. Practical Radiation Oncology, 2022, , .	2.1	0
535	Findings on Diagnostic Magnetic Resonance Imaging Before Radiotherapy for Prostate Cancer. Canadian Association of Radiologists Journal, 0, , 084653712211372.	2.0	0
536	Post-Surgical Strategies for Prostate Cancer: Clinicopathologic and Genomics Criteria. European Medical Journal Oncology, 0, , 70-77.	0.0	0
537	Predictive Models in Prostate Cancer. , 2022, , 217-225.		0
538	Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer. BMC Urology, 2022, 22, .	1.4	0
539	The Development of a Gleason Score-Related Gene Signature for Predicting the Prognosis of Prostate Cancer. Journal of Clinical Medicine, 2022, 11, 7164.	2.4	1

#	Article	IF	Citations
540	Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. Cancers, 2022, 14, 6094.	3.7	4
541	PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2023, 116, 779-787.	0.8	5
542	A preoperative magnetic resonance imaging-based model to predict biochemical failure after radical prostatectomy. Scientific Reports, 2023, 13, .	3.3	1
543	Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy. Archivio Italiano Di Urologia Andrologia, 2022, 94, 390-395.	0.8	1
544	Incremental prognostic value of ADC histogram analysis in patients with high-risk prostate cancer receiving adjuvant hormonal therapy after radical prostatectomy. Frontiers in Oncology, 0, 13, .	2.8	0
545	Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imaginingâ€targeted biopsy. Prostate, 0, , .	2.3	0
546	Variations in genomic regions encoding long non-coding RNA genes associated with increased prostate cancer risk. Mutation Research - Reviews in Mutation Research, 2023, 791, 108456.	5.5	2
547	Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: The PARTIAL trial. Contemporary Clinical Trials, 2023, 128, 107168.	1.8	2
548	The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. Advances in Radiation Oncology, 2023, 8, 101193.	1.2	0
549	Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the <scp>V</scp> an <scp>DAAM</scp> study. Cancer Medicine, 2023, 12, 1869-1877.	2.8	1
550	Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. European Urology, 2023, 84, 9-12.	1.9	1
551	Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 2023, 388, 1547-1558.	27.0	150
552	Beyond diagnosis: is there a role for radiomics in prostate cancer management?. European Radiology Experimental, 2023, 7, .	3.4	6
553	Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7305-7317.	2.5	2
554	Prediction of pelvic lymph node metastases and PSMA PET positive pelvic lymph nodes with multiparametric MRI and clinical information in primary staging of prostate cancer. European Journal of Radiology Open, 2023, 10, 100487.	1.6	1
555	Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial. Frontiers in Oncology, 0, 13, .	2.8	0
556	A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. British Journal of Cancer, 0, , .	6.4	3
557	Role of radiomic analysis of [18F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging. European Radiology, 0, , .	4.5	0

#	ARTICLE	IF	CITATIONS
558	PSA density does not improve predictive accuracy of the UCSFâ€CAPRA score. Prostate, 0, , .	2.3	0
560	The Transcriptomic Profiles of ESR1 and MMP3 Stratify the Risk of Biochemical Recurrence in Primary Prostate Cancer beyond Clinical Features. International Journal of Molecular Sciences, 2023, 24, 8399.	4.1	3
561	Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer. European Urology Focus, 2023, 9, 983-991.	3.1	0
563	The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer. Urology, 2023, 178, 114-119.	1.0	0
564	Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. Seminars in Radiation Oncology, 2023, 33, 232-242.	2.2	0
565	Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. , 2023, 2, .		3
566	A seven-gene prognosis model to predict biochemical recurrence for prostate cancer based on the TCGA database. Frontiers in Surgery, 0, 9, .	1.4	2
567	Novel Multiparametric Magnetic Resonance Imaging-Based Deep Learning and Clinical Parameter Integration for the Prediction of Long-Term Biochemical Recurrence-Free Survival in Prostate Cancer after Radical Prostatectomy. Cancers, 2023, 15, 3416.	3.7	3
568	Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2023, , .	1.6	0
569	Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?. International Journal of Molecular Sciences, 2023, 24, 12508.	4.1	0
570	MRIç›å...³å½±åå£°å¦ç”¨å¨¡¡åž‹è¯""äºŽå‰â—è...ºç™Œè¯Šæ–ã€ä¾µµ¢æ€§å’Œé¢„åŽ¯è¯„ä¼°. Journal of Zhejiang University: Science B, 202.	2.2	2
571	A matched-analysis on short-term and long-term (up to 5 years of follow-up) urinary incontinence outcomes after robot-assisted radical prostatectomy with and without anterior and posterior reconstruction: data on 1358 patients. International Urology and Nephrology, 0, , .	1.4	0
572	Diagnostic performance of prediction models for extraprostatic extension in prostate cancer: a systematic review and meta-analysis. Insights Into Imaging, 2023, 14, .	3.4	0
573	Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives. Cancers, 2023, 15, 4746.	3.7	3
574	Tenâ€year work burden after prostate cancer treatment. Cancer Medicine, 2023, 12, 19234-19244.	2.8	0
575	Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. European Urology, 2023, 84, 588-596.	1.9	3
576	Prostate cancer nomograms and their application in Asian men: a review. Prostate International, 2023, , .	2.3	2
579	Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence. British Journal of Cancer, 0, , .	6.4	0

#	Article	IF	Citations
580	Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort. Frontiers in Oncology, 0, 13, .	2.8	0
581	Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	1
582	Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. American Journal of Roentgenology, 2023, 221, 773-787.	2.2	3
583	MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer. Abdominal Radiology, 0, , .	2.1	0
584	Large cribriform glands (>â€‰0.25â€‰mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer. Histopathology, 2024, 84, 614-623.	2.9	0
585	Prostateâ€derived circulating microRNAs add prognostic value to prostate cancer risk calculators. , 2023, 2, .		0
586	Multiparametric MRI-based 5-year Risk Prediction Model for Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy. Radiology, 2023, 309, .	7.3	2
587	The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort. European Urology Oncology, 2023, , .	5.4	0
588	Grossing and reporting of radical prostatectomy specimens: An evidence-based approach. Indian Journal of Cancer, 2023, .	0.2	0
589	A prospective cohort of men with localized prostate cancer on active surveillance protocol in Hong Kong, China: what did we learn?. Asian Journal of Andrology, 2024, 26, 245-249.	1.6	0
590	The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer. Cancers, 2024, 16, 939.	3.7	0
591	Deep learning-based radiomics model from pretreatment ADC to predict biochemical recurrence in advanced prostate cancer. Frontiers in Oncology, 0, 14, .	2.8	0
592	Prostate cancer risk stratification via eNose urine odor analysis: a preliminary report. Frontiers in Oncology, 0, 14, .	2.8	0